Key result
Fluoxetine administration significantly reduced NLRP3 inflammasome activation, decreased brain edema, and improved neurological function at 24 hours after subarachnoid hemorrhage in rats.
Why the study?
Does fluoxetine improve early brain injury and neurological function in a rat model of subarachnoid hemorrhage?
Does fluoxetine improve early brain injury and neurological function in a rat model of subarachnoid hemorrhage?
p-value: p=<0.05
Fluoxetine mitigates early brain injury after subarachnoid hemorrhage in rats by inhibiting NLRP3 inflammasome activation through autophagy.
Hypothesis-generating for fluoxetine in subarachnoid hemorrhage; human trials needed before any clinical consideration.
BACKGROUND: The NLRP3 inflammasome is a multiprotein complex that regulates the innate immune inflammatory response by activating caspase-1 and subsequent IL-1β and IL-18. Fluoxetine has been shown to have the anti-inflammatory properties in many disease models. However, the effects and mechanisms of these effects of fluoxetine in early brain injury after subarachnoid hemorrhage (SAH) have not been defined. METHODS: The SAH model was induced by an endovascular perforation in adult male Sprague-Dawley (SD) rats weighing 300-320 g. N-Ac-Tyr-Val-Ala-Asp-chloromethyl ketone (AC-YVAD-CMK) was injected intraperitoneally (5 mg/kg) 1 h after SAH. Fluoxetine was administered via intravenous route 6 h after SAH. 3-Methyladenine (3-MA) was intracerebroventricularly injected 20 min before SAH. SAH grade, neurological function, brain water content, propidium iodide (PI) staining, western blot, double immunostaining, and transmission electron microscopy were performed. RESULTS: Expression of caspase-1 increased and peaked at 24 h after SAH. Caspase activation was along with the increased necrotic cells, which occurred mainly in neurons. Necrotic cell death of microglia and astrocyte were also found. Administration of AC-YVAD-CMK, a caspase-1 inhibitor, reduced the expression of IL-1β and IL-18 and the number of PI-positive cells, attenuated brain edema, and improved neurological function, which was also observed in fluoxetine-treated rats. Furthermore, fluoxetine treatment significantly decreased the expression of NLRP3 and cleaved caspase-1 and upregulated the expression of beclin-1, a marker for autophagy. Finally, the effects of fluoxetine in NLRP3 inflammasome activation were reversed by additional 3-MA administration. CONCLUSIONS: Together, our present study indicated that NLRP3 inflammasome and caspase-1 activation play a deleterious role in early brain injury and fluoxetine mitigates NLRP3 inflammasome and caspase-1 activation through autophagy activation after SAH, providing a potential therapeutic agent for SAH treatment.
No takes yet. Share an insight, caveat, or question.
Li et al. (2017) studied Subarachnoid hemorrhage (SAH) (n=271). Fluoxetine vs. Vehicle (0.9% NaCl) was evaluated on NLRP3 inflammasome activation, brain edema, and neurological function (p=<0.05). Fluoxetine administration significantly reduced NLRP3 inflammasome activation, decreased brain edema, and improved neurological function at 24 hours after subarachnoid hemorrhage in rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: